ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of our drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. The Company's drug candidates are small molecules, which are orally administered, offering significant quality of life benefits, since patients swallow a capsule or pill instead of having to visit a clinic for an infusion or undergo an injection.

Employee Rating

2.3More
TypePublic
HQMountain View, US
Founded1997
Size (employees)66 (est)+7%
Websitechemocentryx.com
ChemoCentryx was founded in 1997 and is headquartered in Mountain View, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at ChemoCentryx

Thomas J. Schall

Thomas J. Schall

President, Chief Executive Officer and Chairman of the Board
Markus J. Cappel

Markus J. Cappel

Chief Business Officer and Treasurer
Show more

ChemoCentryx Office Locations

ChemoCentryx has an office in Mountain View
Mountain View, (HQ)
850 Maude Avenue
Show all (1)
Report incorrect company information

ChemoCentryx Financials and Metrics

ChemoCentryx Revenue

ChemoCentryx's revenue was reported to be $82.50 m in FY, 2017
USD

Net income (Q3, 2018)

(10.9m)

EBIT (Q3, 2018)

(11.5m)

Market capitalization (4-Dec-2018)

516.9m

Closing stock price (4-Dec-2018)

10.2

Cash (30-Sep-2018)

24.1m

EV

507.5m
ChemoCentryx's current market capitalization is $516.9 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

11.9m82.5m

General and administrative expense

11.6m14.5m14.7m16.5m

R&D expense

33.5m33.2m37.9m49.5m

Operating expense total

45.2m47.7m52.7m66.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

2.8m4.3m8.2m8.9m9.0m9.5m

General and administrative expense

2.9m3.5m3.4m3.5m3.7m3.6m3.8m4.1m3.9m3.2m4.6m4.2m3.6m4.7m4.7m5.4m

R&D expense

8.2m8.1m9.0m7.5m8.4m8.6m7.9m11.2m9.1m8.4m10.0m14.3m12.3m14.7m17.8m15.1m

Operating expense total

11.1m11.7m12.4m11.1m12.1m12.2m11.7m15.3m12.9m11.6m14.5m18.5m15.9m19.4m22.5m20.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

10.3m16.1m12.8m12.0m40.0m

Accounts Receivable

30.2m51.1m

Inventories

596.0k972.0k757.0k722.0k

Current Assets

134.3m74.3m72.0m148.7m179.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

22.3m11.6m13.1m20.9m25.4m11.6m14.6m13.4m21.9m13.9m19.0m21.5m18.0m30.6m68.8m24.1m

Accounts Receivable

175.0k120.0k30.2m218.0k530.0k1.7m164.0k336.0k

Inventories

1.3m

Current Assets

125.6m133.7m100.8m86.1m76.1m71.4m74.2m65.2m127.0m122.7m119.9m124.2m122.4m149.8m184.9m176.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(38.7m)(46.9m)(47.3m)(40.0m)17.9m

Depreciation and Amortization

576.0k543.0k477.0k348.0k418.0k

Inventories

Accounts Payable

159.0k(161.0k)(73.0k)(4.0k)729.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(29.1m)(11.5m)(12.3m)(34.7m)(12.0m)(24.1m)(11.6m)(15.2m)(25.2m)(32.3m)(6.0m)(15.2m)(21.8m)(9.4m)(16.3m)(27.2m)

Depreciation and Amortization

426.0k153.0k414.0k259.0k86.0k173.0k260.0k203.0k311.0k111.0k227.0k371.0k

Inventories

1.3m

Accounts Payable

(58.0k)(199.0k)690.0k121.0k809.0k280.0k615.0k619.0k(162.0k)165.0k819.0k704.0k682.0k(951.0k)(378.0k)(824.0k)
USDY, 2018

EV/EBIT

-44 x

EV/CFO

16 x

Debt/Equity

0.7 x

Debt/Assets

0.1 x

Financial Leverage

8.9 x
Show all financial metrics
Report incorrect company information

ChemoCentryx News and Updates

ChemoCentryx Announces Proposed Public Offering of Common Stock

MOUNTAIN VIEW, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock.  In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to pu…
Report incorrect company information

ChemoCentryx Blogs

ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock

MOUNTAIN VIEW, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (Nasdaq:CCXI) announced today that it will not conclude an offering of shares of its common stock as announced on Wednesday, September 26, 2018 .

ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday October 2, 2018 at 1:40 p.m. ET .

ChemoCentryx Company Life and Culture

Report incorrect company information

ChemoCentryx Frequently Asked Questions

  • When was ChemoCentryx founded?

    ChemoCentryx was founded in 1997.

  • Who are ChemoCentryx key executives?

    ChemoCentryx's key executives are Thomas J. Schall and Markus J. Cappel.

  • How many employees does ChemoCentryx have?

    ChemoCentryx has 66 employees.

  • What is ChemoCentryx revenue?

    Latest ChemoCentryx annual revenue is $82.5 m.

  • What is ChemoCentryx revenue per employee?

    Latest ChemoCentryx revenue per employee is $1.2 m.

  • Who are ChemoCentryx competitors?

    Competitors of ChemoCentryx include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

  • Where is ChemoCentryx headquarters?

    ChemoCentryx headquarters is located at 850 Maude Avenue, Mountain View.

  • Where are ChemoCentryx offices?

    ChemoCentryx has an office in Mountain View.

  • How many offices does ChemoCentryx have?

    ChemoCentryx has 1 office.